Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.42 |
| ▸ | MPL | P40238 | 3/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064356 | 1.00 | RORC (0.42) | RORCMPLP2RY12MAPTSMN1; SMN2 | |
| SCHEMBL23064353 | 1.00 | RORC (0.42) | RORCMPLP2RY12MAPTSMN1; SMN2 | |
| SCHEMBL31050098 | 0.93 | RORC (0.48) | RORCMPLP2RY12MAPTSMN1; SMN2 | |
| SCHEMBL23064362 | 0.87 | P2RX7 (0.43) | RORCHSD11B1 | |
| SCHEMBL23064361 | 0.87 | P2RX7 (0.43) | RORCHSD11B1 | |
| SCHEMBL23283045 | 0.85 | P2RY12 (0.47) | RORCP2RY12SLC2A1 | |
| SCHEMBL23064339 | 0.84 | P2RY12 (0.48) | P2RY12SMN1; SMN2MEN1KMT2A | |
| SCHEMBL23064338 | 0.84 | P2RY12 (0.48) | P2RY12SMN1; SMN2MEN1KMT2A | |
| SCHEMBL25844259 | 0.82 | TRPA1 (0.48) | TRPV1HSD11B1 | |
| SCHEMBL23064370 | 0.79 | TRPV1 (0.47) | P2RY12MAPTSMN1; SMN2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170116-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | OSAKA UNIVERSITY (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250073229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | SHINSHU UNIVERSITY (JP) | 2025-03-06 | — | — | US | disclosed |
| CN-118678955-A | Pharmaceutical composition for preventing and/or treating heart failure | 国立大学法人大阪大学 | 2024-09-20 | — | — | CN | disclosed |
| US-20240307375-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | KYOTO UNIVERSITY (JP) | 2024-09-19 | — | — | US | disclosed |
| CN-112204017-B | Benzisoxazole compounds | 国立大学法人大阪大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-117580577-A | Pharmaceutical composition for preventing and/or treating kidney injury and autophagy activator | 国立大学法人大阪大学 | 2024-02-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307375-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | ATG7, BECN1, SQSTM1 | RORC 1342/4885MPL 3723/4885P2RY12 465/4885 |
| US-20250170116-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | REN, ATP6V1B1, CYP2S1 | RORC 859/4885MPL 3916/4885P2RY12 834/4885 |
| US-20250073229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | CBR1, CYP2S1, CYP2F1 | RORC 600/4885MPL 3385/4885P2RY12 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.